102676-87-9
102676-87-9 structure
- Name: (R)-Fadrozole
- Chemical Name: (R)-Fadrozole
- CAS Number: 102676-87-9
- Molecular Formula: C14H13N3
- Molecular Weight: 223.27
- Catalog: Research Areas Cardiovascular Disease
- Create Date: 2021-10-18 20:51:48
- Modify Date: 2025-08-27 17:39:50
-
(R)-Fadrozole ((R)-CGS 16949A; FAD286) is a potent nonsteroidal inhibitor[1]. (R)-Fadrozole also inhibits human placental aromatase (pIC50 = 6.17) and aldosterone biosynthesis. (R)-Fadrozole reverses cardiac fibrosis in spontaneously hypertensive heart failure rats.[1][2].
| Name | (R)-Fadrozole |
|---|
| Description | (R)-Fadrozole ((R)-CGS 16949A; FAD286) is a potent nonsteroidal inhibitor[1]. (R)-Fadrozole also inhibits human placental aromatase (pIC50 = 6.17) and aldosterone biosynthesis. (R)-Fadrozole reverses cardiac fibrosis in spontaneously hypertensive heart failure rats.[1][2]. |
|---|---|
| Related Catalog | |
| Target |
pIC50: 6.17 (human placental aromatase) |
| In Vitro | The (-)-enantiomer with the S-absolute configuration was responsible for the high aromatase inhibitory activity of (R)-Fadrozole[1]. |
| In Vivo | (R)-fadrozole (0.24 and 1.2 mg/kg; daily; oral) and (S)-fadrozole similarly decreases plasma aldosterone levels, whereas urinary aldosterone excretion rate was reduced only by S-fadrozole[2]. (R)-fadrozole (0.24 and 1.2 mg/kg; daily; oral) effectively reverses preexistent left ventricular interstitial fibrosis by 50% (vs. 42% for canrenoate), S-fadrozole was devoid of an antifibrotic effect[2]. Animal Model: SHHF rats[2] Dosage: 0.24 and 1.2 mg/kg Administration: Daily; oral Result: Decreased plasma aldosterone levels and reversed preexistent left ventricular interstitial fibrosis. |
| References |
| Molecular Formula | C14H13N3 |
|---|---|
| Molecular Weight | 223.27 |
| Hazard Codes | Xi |
|---|